Author ORCID Identifier
School of Pharmacy
Abstract: Targeted alpha-particle therapy (TAT) aims to selectively deliver radionuclides emitting α-particles (cytotoxic payload) to tumors by chelation to monoclonal antibodies, peptides or small molecules that recognize tumor-associated antigens or cell-surface receptors. Because of the high linear energy transfer (LET) and short range of alpha (α) particles in tissue, cancer cells can be significantly damaged while causing minimal toxicity to surrounding healthy cells. Recent clinical studies have demonstrated the remarkable efficacy of TAT in the treatment of metastatic, castration-resistant prostate cancer. In this comprehensive review, we discuss the current consensus regarding the properties of the α-particle-emitting radionuclides that are potentially relevant for use in the clinic; the TAT-mediated mechanisms responsible for cell death; the different classes of targeting moieties and radiometal chelators available for TAT development; current approaches to calculating radiation dosimetry for TATs; and lead optimization via medicinal chemistry to improve the TAT radiopharmaceutical properties. We have also summarized the use of TATs in pre-clinical and clinical studies to date
Digital Commons Citation
Tafreshi, Narges K.; Doligalski, Michael L.; Tichacek, Christopher J.; Pandya, Darpan N.; Budzevich, Mikalai M.; el-Haddad, Ghassan; Khushalani, Nikhil I.; Moros, Eduardo G.; McLaughlin, Mark L.; Wadas, Thaddeus J.; and Morse, David L., "Development of Targeted Alpha Particle Therapy for Solid Tumors" (2019). Faculty & Staff Scholarship. 1419.
Tafreshi, N. K., Doligalski, M. L., Tichacek, C. J., Pandya, D. N., Budzevich, M. M., El-Haddad, G., Khushalani, N. I., Moros, E. G., McLaughlin, M. L., Wadas, T. J., & Morse, D. L. (2019). Development of Targeted Alpha Particle Therapy for Solid Tumors. Molecules, 24(23), 4314. https://doi.org/10.3390/molecules24234314